Login to Your Account



FDA Advisers Oppose Wider Label For Factive In Sinusitis

By Aaron Lorenzo


Wednesday, September 13, 2006
GAITHERSBURG, Md. - The FDA's Anti-Infective Drugs Advisory Committee voted against expanding the label for Factive (gemifloxacin) to include acute bacterial sinusitis, absent an additional study to demonstrate its superiority. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription